Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 11,574 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Kidney Disease (CKD)
Interventions: CKD Registry, ATSM + Health Coach, Usual care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Chronic Stroke, Cerebral Palsy, Parkinson's Disease
Interventions: Gondola AMPS; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions: Momelotinib, Azacitidine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Graft-vs.-Host Disease
Interventions: Alemtuzumab (Campath); Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease, Valvular Disease, Chronic Stable Angina, Chronic Stable Heart Failure
Interventions: Hospital-based CR + Movn Application, Choice of Hospital or home-based CR + Movn Application, Hospital-based CR + Movn Application + Nudge, Choice of Hospital or home-based CR + Movn Application + Nudge; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 100 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Filgrastim, Cladribine, Cyclosporine, Cytarabine (Ara-C), Fludarabine Phosphate, Idarubicin, Methylprednisolone, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 55 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: Panobinostat (LBH589), 5-Azacytidine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 8
States / cities: Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: End Stage Renal Disease, Hemodialysis
Interventions: Alpha tocopherol; Drug
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 13
States / cities: Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more

Conditions: Hepatitis C Virus, Hiv Infections
Interventions: bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more

Conditions: Chronic Kidney Disease
Interventions: collection of serum/capillary creatinine values; Diagnostic Test
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more

Conditions: Posttraumatic Stress Disorder
Interventions: High THC cannabis, High CBD cannabis, THC/CBD cannabis, Placebo cannabis; Drug
Lead sponsor: Multidisciplinary Association for Psychedelic Studies; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis
Interventions: There is no intervention; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 13 more

Conditions: COPD
Interventions: LAIV; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Stroke
Interventions: Ischemic Conditioning, Sham; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cough, Reflux
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: veliparib, pharmacological study, biopsy; Drug · Other · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Post-Traumatic Stress Disorder, Marijuana Abuse
Interventions: Brief Imaginal Exposure; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
Interventions: Ruxolitinib, Enasidenib; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 6 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Dolastatin 10; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Migraine
Interventions: cyclobenzaprine hydrochloride, placebo; Drug
Lead sponsor: Kennedy Medical Group; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cherry Hill, New Jersey

Conditions: Chronic Myeloid Leukemia
Interventions: Omacetaxine mepesuccinate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 7 more

Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Articular Cartilage Disorder, Degeneration; Articular Cartilage, Chronic Cartilage Injury, Acute Cartilage Injury, Defect of Articular Cartilage
Interventions: Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft), Microfracture; Biological · Other
Lead sponsor: ISTO Technologies, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Santa Monica, California • Chicago, Illinois + 5 more

Search by objective public record fields.

Kidney Awareness Registry and Education

Gondola Mechanism of Action

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Campath in Chronic GVHD

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Oxidative Stress and Hemodialysis Access Failure

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

Transformative Research in Diabetic Nephropathy

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

Ischemic Conditioning as an Intervention to Improve Motor Function in Chronic Stroke

Cough Monitoring Study

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Short-Term Exposure for PTSD

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Neocartilage Implant to Treat Cartilage Lesions of the Knee